Illumina advances personalized cancer care with new pharma development partnerships
Illumina (NASDAQ:ILMN) has announced new partnerships with global pharmaceutical companies to develop companion diagnostics (CDx) for the KRAS biomarker using their TruSight™ Oncology Comprehensive genomic profiling test.
The partnerships aim to advance personalized cancer care by helping clinicians match patients with targeted therapies based on genetic mutations. KRAS, one of the most commonly mutated oncogenes in cancer, has historically been difficult to target. The CDx development will enable broader identification of patients who may benefit from targeted therapies, regardless of tumor origin.
The initiative represents a significant advancement in precision oncology, particularly for traditionally difficult-to-treat diseases like pancreatic ductal adenocarcinoma. The genomic profiling capabilities will help improve patient prognostication and treatment decisions through better understanding of KRAS-driven tumor biology.
Illumina (NASDAQ:ILMN) ha annunciato nuove collaborazioni con aziende farmaceutiche globali per sviluppare diagnostici compagni (CDx) per il biomarcatore KRAS utilizzando il test di profilo genomico completo TruSight™ Oncology Comprehensive.
Le partnership mirano a far progredire la medicina personalizzata del cancro, aiutando i medici ad abbinare i pazienti a terapie mirate basate su mutazioni genetiche. KRAS, uno degli oncogeni più spesso mutati, è storicamente difficile da bersagliare. lo sviluppo del CDx permetterà una identificazione più ampia dei pazienti che possono beneficiare di terapie mirate, indipendentemente dall’origine del tumore.
Questa iniziativa rappresenta un notevole avanzamento nell’oncologia di precisione, soprattutto per malattie tradizionalmente complesse da trattare come l’adenocarcinoma ductale pancreatico. Le capacità di profiling genomico aiuteranno a migliorare la prognosi dei pazienti e le decisioni terapeutiche grazie a una migliore comprensione della biologia dei tumori guidata da KRAS.
Illumina (NASDAQ:ILMN) ha anunciado nuevas colaboraciones con compañías farmacéuticas globales para desarrollar diagnósticos complementarios (CDx) para el biomarcador KRAS utilizando su prueba de perfil genomico completo TruSight™ Oncology Comprehensive.
Las asociaciones buscan avanzar en la medicina personalizada del cáncer, ayudando a los médicos a emparejar a los pacientes con terapias dirigidas basadas en mutaciones genéticas. KRAS, uno de los oncogenes más frecuentemente mutados, ha sido históricamente difícil de dirigirse. El desarrollo del CDx permitirá una identificación más amplia de los pacientes que podrían beneficiarse de terapias dirigidas, independientemente del origen del tumor.
La iniciativa representa un avance significativo en la oncología de precisión, especialmente para enfermedades tradicionalmente difíciles de tratar como el adenocarcinoma ductal pancreático. Las capacidades de perfil genomico ayudarán a mejorar la prognóstico de los pacientes y las decisiones de tratamiento mediante una mejor comprensión de la biología tumoral impulsada por KRAS.
Illumina(NASDAQ:ILMN)이 글로벌 제약사들과 새로운 동반 진단(CDx) 개발을 위한 파트너십을 발표했습니다. KRAS 바이오마커를 대상으로 TruSight™ Oncology Comprehensive의 유전체 프로파일링 테스트를 사용합니다.
이 파트너십은 개인 맞춤형 암 치료를 촉진하여, 유전적 돌연변이에 기반한 표적 치료와 환자 매칭을 돕는 것을 목표로 합니다. KRAS는 암에서 흔히 변이가 생기는 종양 유전자 중 하나로, 과거에는 표적으로 삼기 어려웠습니다. CDx 개발은 종양의 기원과 관계없이 표적 치료의 혜택을 받을 수 있는 환자 식별을 넓힐 수 있게 해줄 것입니다.
이 이니셔티브는 정밀 종양학에서 상당한 진전으로, 췌장관암처럼 전통적으로 치료가 어려운 질환에 특히 의미가 큽니다. 유전체 프로파일링 기능은 KRAS기반 종양 생물학에 대한 이해를 높여 환자의 예후 예측과 치료 의사결정을 개선하는 데 기여할 것입니다.
Illumina (NASDAQ:ILMN) a annoncé de nouveaux partenariats avec des entreprises pharmaceutiques mondiales afin de développer des diagnostics compagnons (CDx) pour le biomarqueur KRAS en utilisant leur test de profilage génomique global TruSight™ Oncology Comprehensive.
Ces partenariats visent à faire progresser les soins personnalisés du cancer en aidant les cliniciens à associer les patients à des thérapies ciblées basées sur des mutations génétiques. KRAS, l’un des oncogènes les plus fréquemment mutés, a historiquement été difficile à cibler. Le développement du CDx permettra d’identifier plus largement les patients susceptibles de bénéficier de thérapies ciblées, quel que soit l’origine tumorale.
Cette initiative représente une avancée importante en oncologie de précision, notamment pour des maladies traditionnellement difficiles à traiter comme l’adénocarcinome canalopancréatique. Les capacités de profiling génomique aideront à améliorer la pronostic des patients et les décisions thérapeutiques grâce à une meilleure compréhension de la biologie tumorale pilotée par KRAS.
Illumina (NASDAQ:ILMN) hat neue Partnerschaften mit globalen Pharmaunternehmen angekündigt, um Companion Diagnostics (CDx) für den KRAS-Biomarker mithilfe ihres TruSight™ Oncology Comprehensive-Genomprofiling-Tests zu entwickeln.
Ziel der Partnerschaften ist es, die personalisierte Krebstherapie voranzutreiben und Klinikern zu helfen, Patienten basierend auf genetischen Mutationen mit gezielten Therapien zu matched. KRAS, eines der am häufigsten mutierten Onkogene im Krebs, war historisch schwer zu zielgerichtet. Die CDx-Entwicklung wird eine breitere Identifikation von Patienten ermöglichen, die von gezielten Therapien profitieren könnten, unabhängig von der Tumorherkunft.
Die Initiative stellt einen bedeutenden Fortschritt in der Präzisionsonkologie dar, insbesondere für traditionell schwer behandelbare Erkrankungen wie das duktale pankreatische Adenokarzinom. Die genomische Profiling-Fähigkeiten werden dazu beitragen, die Patientenprognose und die Behandlungsentscheidungen durch ein besseres Verständnis der KRAS-getriebenen Tumorbiologie zu verbessern.
Illumina (NASDAQ:ILMN) أعلن عن شراكات جديدة مع شركات أدوية عالمية لتطوير تشخيصات مصاحبة (CDx) لـ عامل KRAS الحيوي باستخدام اختبار التحليل الجينومي الشامل TruSight™ Oncology Comprehensive.
تهدف الشراكات إلى تعزيز رعاية السرطان المخصصة من خلال مساعدة الأطباء في مطابقة المرضى بعلاجات مستهدفة تستند إلى الطفرات الوراثية. KRAS، أحد أكثر جينات الأورام تغيراً، كان من الصعب استهدافه تاريخياً. سيمكن تطوير CDx من تحديد عدد أوسع من المرضى الذين قد يستفيدون من العلاجات المستهدفة، بغض النظر عن أصل الورم.
يمثل ذلك تقدماً مهماً في علم الأورام الدقيق، خاصةً للأمراض التي يصعب علاجها تقليدياً مثل سرطان البنكرياس القنوي القطني. ستساعد قدرات التحليل الجينومي في تحسين توقعات المرضى وقرارات العلاج من خلال فهم أفضل لبيولوجيا الأورام المدفوعة بـKRAS.
Illumina (NASDAQ:ILMN) 宣布与全球制药公司建立新的合作伙伴关系，以使用其 TruSight™ Oncology Comprehensive 基因组分析检测开发用于 KRAS 生物标志的伴随诊断（CDx）。
这些伙伴关系旨在通过帮助临床医生基于基因突变将患者与靶向治疗相匹配来推进个性化癌症治疗。KRAS 是癌症中最常突变的致癌基因之一，历来难以靶向。CDx 的开发将使更多可能从靶向治疗中受益的患者得以识别，与肿瘤来源无关。
这一举措在精准肿瘤学领域具有重要进展，尤其是对如胰腺导管腺癌等传统治疗困难的疾病。基因组分析能力将通过更好地理解 KRAS 驱动的肿瘤生物学，帮助改善患者预后与治疗决策。
- Development of companion diagnostics for historically challenging KRAS biomarker
- Expansion of tumor-agnostic CDx claims for broader patient identification
- Enhanced ability to match patients with targeted therapies across cancer types
- Potential improvement in treatment outcomes for difficult-to-treat cancers
- Historical challenges in targeting KRAS mutations
- Complex development and regulatory approval process for companion diagnostics
- Potential manufacturing and implementation challenges mentioned in forward-looking statements
Insights
Illumina's new pharma partnerships to develop KRAS companion diagnostics strengthen its position in the growing precision oncology market.
Illumina's announcement of multiple pharmaceutical partnerships to develop companion diagnostics (CDx) for KRAS biomarkers represents a strategic expansion of its precision oncology portfolio. By integrating these CDx claims into their TruSight™ Oncology Comprehensive genomic profiling test, Illumina is positioning itself at the intersection of diagnostics and targeted therapy selection – a critical growth area in oncology.
KRAS mutations are particularly significant targets because they appear in approximately 25% of all tumors and have historically been considered "undruggable." Recent breakthroughs in KRAS-targeted therapies have changed this paradigm, creating substantial demand for reliable testing to identify eligible patients. This explains why Illumina is pursuing partnerships with multiple pharmaceutical companies simultaneously rather than an exclusive arrangement.
The tumor-agnostic approach Illumina is taking with these companion diagnostics is especially valuable. Instead of developing separate tests for each cancer type, their platform can identify actionable KRAS mutations regardless of the tumor's origin. This universality enhances the commercial potential of their diagnostic platform while simplifying implementation for healthcare providers.
For Illumina's business model, these partnerships create multiple revenue opportunities: initial test sales, potential royalties from associated therapies, and establishing their platform as the standard for precision oncology testing. As pharmaceutical companies continue developing targeted therapies for previously "undruggable" genetic drivers, Illumina's comprehensive genomic profiling infrastructure becomes increasingly valuable.
The timing aligns with broader market shifts toward targeted therapies and biomarker-driven treatment selection across oncology, positioning Illumina to capture value in both the diagnostic and therapeutic segments of the precision medicine ecosystem.
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker
"Developing companion diagnostic claims for the historically important KRAS biomarker will enable broader identification of patients who may benefit from targeted therapies, regardless of tumor origin," said Traci Pawlowski, vice president and head of Clinical Solutions at Illumina. "This marks a critical step forward as we build our clinical offerings to support clinicians and pharmaceutical partners in delivering more personalized, effective, and broadly accessible precision cancer care."
Genomic profiling with CDx helps match patients to precision therapies
CDx built on TSO Comprehensive help clinicians match patients with approved targeted therapies based on the genetic mutations underlying their cancer. TSO Comprehensive does this by generating a molecular tumor profile that can identify the genetic mutations driving cancer growth. To target those underlying mutations, clinicians use the CDx to confirm whether a patient is a candidate for a targeted therapy or clinical trial.
KRAS is one of the most commonly mutated oncogenes in cancer, driving tumor proliferation, survival, and progression. Given its prominence in cellular transformation, previous research has demonstrated that identifying KRAS variants is critical for proper therapy selection and improving patient outcomes.1,2
Genomics paves the way in precision oncology
Recent advances using genomics to detect KRAS variants have been successfully demonstrated across cancer types despite historical challenges in targeting KRAS. This includes traditionally difficult-to-treat diseases like pancreatic ductal adenocarcinoma, leading to opportunities for improved prognostication and treatment decisions.1,2 Genomics insights into KRAS both enhance our understanding of KRAS-driven tumor biology and pave the way for more personalized therapeutic strategies.
"KRAS mutations are common across cancer types but have historically been difficult to address," said Kashif Firozvi, MD, Maryland Oncology Hematology. "The field is evolving rapidly, with new therapies better suited to patients with mutations in this once 'undruggable' gene. As the treatment landscape expands, including drugs that target the KRAS pathway, knowing a patient's KRAS status becomes essential to guiding effective treatment protocols and improving outcomes."
Illumina maintains a growing pipeline of CDx claims under development through partnerships with pharmaceutical companies, which will continue to support groundbreaking targeted therapies and immunotherapies to make a difference in the lives of patients with cancer.
To learn more about TruSight Oncology Comprehensive, click here.
References:
- Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends in Cancer. 2025;11(2): 91-116. doi:10.1016/j.trecan.2024.11.009
- Fakih MM. KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer. 2010;9(1): 22-30. doi:10.3816/CCC.2010.n.003
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; (iii) legislative, regulatory and economic developments; (iv) our ability to manufacture robust instrumentation and consumables; (iv) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Brian Blanchett
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-advances-personalized-cancer-care-with-new-pharma-development-partnerships-302564027.html
SOURCE Illumina, Inc.
FAQ
What is Illumina's new partnership announcement for cancer diagnostics?
How will ILMN's KRAS companion diagnostics benefit cancer patients?
What is the significance of KRAS in cancer treatment?
How does Illumina's TruSight Oncology Comprehensive test work?
What types of cancers will benefit from Illumina's KRAS diagnostics?
